



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

4th February, 2019

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q3

Please find enclosed a press release issued by the Company in respect of financial results for the third quarter ended 31st December 2018.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary



PRESS RELEASE

Monday, 4th February 2019, Mumbai

GlaxoSmithKline Pharmaceuticals Limited delivers strong Q3 performance with Revenue up 17% and PAT higher by 26%.

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 31st December, 2018. Revenue for the quarter came in at Rs.825 crores, recording a growth of 17% as compared to the same prior year period. Profit Before Tax (PBT) at Rs. 170 crores grew by 21% and Profit After Tax (PAT) at Rs.113 crores grew by 26%.

Revenue for the nine months ended 31st December 2018, came in at Rs.2377 crores, growing 11% as compared to the same prior year period. Profit Before Tax (PBT) at Rs.464 crores and Profit After Tax (PAT) at Rs.302 crores are higher by 27% and 23% respectively, against the same prior year period.

Commenting on the results, **A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

"The business embarked on its new strategy this year, as we put in place an optimal commercial structure and worked at building capability.

Our new commercial model is in place, with increased focus on our priority brands, and expansion in our field force to drive this focus, including a new trade channel strategy. Our financial performance highlights the outcomes of this execution with a headline double digit Sales growth both for the quarter and year to date, underpinned by a strong volume delivery.

Exceptional Items for the quarter ended 31st December, 2018 comprise profit from sale of property Rs.23 crores and non-core brand divestments contributing Rs.5 crores."

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts:

Ransom D'Souza

Vice President Corporate Communications and Government Affairs

Email: ransom.a.dsouza@gsk.com

Tel: +91 22 24959203